AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02407444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment & leg cycling
Description: All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale.
Study NCT00945243 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zero-P
Description: The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
Study NCT02371616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium sodium phosphosilicate
Description: 5% w/w calcium sodium phosphosilicate
Study NCT02371616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate
Description: 5% w/w calcium sodium phosphosilicate
Study NCT02371616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: 1426 ppm fluoride as sodium fluoride
Study NCT02371616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: 1426 ppm fluoride as sodium monofluorophosphate
Study NCT02576899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for PTSD and Tobacco Use
Description: ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
Study NCT02576899 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Freedom From Smoking
Description: The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
Study NCT02470741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02470741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Study NCT02470741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00485836 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Study NCT00485836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.3 mg
Description: Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Study NCT00485836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab injection 0.5 mg
Description: Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Study NCT04211376 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT00511719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: 48U
Study NCT00511719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid
Description: 24IU
Study NCT04539418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be monitored during the whole protocol.
Study NCT01871805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as described in the arm descriptions.
Study NCT04539418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K 2
Description: Patients will be monitored during the whole protocol.
Study NCT02308046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole
Study NCT02308046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01181167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban
Study NCT01181167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin sodium
Study NCT04499885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin oil gastric lavage
Description: Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
Study NCT04499885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric lavage with saline and sodium bicarbonate 8.4%
Description: Gastric lavage with saline and sodium bicarbonate 8.4%
Study NCT02657330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBP-101
Description: Subcutaneous drug, escalating dose cohorts
Study NCT03932708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC Core Elements of Outpatient Stewardship
Description: The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
Study NCT00670059 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: single embryo transfer without aneuploidy screening
Description: without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
Study NCT00670059 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: single embryo transfer with aneuploidy screening
Description: with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
Study NCT04630548 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine copper device
Description: The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825mg/m2 BID, PO, daily
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Bolus + IV for 46 hrs on Day 1
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion over 90 min on Day 1
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 200mg/m2 IV 2 hour infusion on Day 1
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 IV infusion for 90minutes on Day 1
Study NCT00070434 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
Study NCT00070434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 50mg TID, PO daily
Study NCT00569985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Description: Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
Study NCT00569985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00569985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00569985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00569985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
Study NCT00966576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Description: 1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
Study NCT01130272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Tablets, orally, twice daily.
Study NCT02407444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy treatment & music listening
Description: All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes.
Study NCT02222428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/BI 54903 XX FDC
Study NCT02222428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 54903 XX
Study NCT02222428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL
Study NCT04112251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavonols Supplement
Description: Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
Study NCT04112251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa Flavonols Supplement
Description: Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
Study NCT04313608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
Study NCT02090829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon (synthetic oxytocin)
Description: Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
Study NCT02090829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control 1
Description: 25g glucose dissolve in 250ml of water
Study NCT05811962 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention, only comparison
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control 2
Description: 25g glucose dissolve in 250ml of water
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Crokao
Description: Standard Crokao containing 25g of available carbohydrate
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 1
Description: Low sugar variant 1 containing 25g of available carbohydrate
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 2
Description: Low sugar variant 2 containing 25g of available carbohydrate
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 3
Description: Low sugar variant 3 containing 25g of available carbohydrate
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 4
Description: Low sugar variant 4 containing 25g of available carbohydrate
Study NCT04653220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 5
Description: Low sugar variant 5 containing 25g of available carbohydrate
Study NCT01884025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Moving and Get Well
Description: Walking Class
Study NCT01884025 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health and Humor Class
Description: Class about the role of humor in health
Study NCT00514137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
Study NCT04871880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.
Study NCT04871880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: Receive routine care
Study NCT03980483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Study NCT03980483 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
Study NCT03980483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
Study NCT03980483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
Study NCT03980483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
Study NCT03980483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cap (containing lactose) to be administered orally.
Study NCT03513393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velpatasvir
Description: Test 1
Study NCT03513393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velpatasvir
Description: Test 2
Study NCT03513393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: velpatasvir
Description: Reference
Study NCT01684410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 HC 100 mg
Description: Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
Study NCT01684410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
Study NCT01130272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets twice daily.
Study NCT02654678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Orodispersible Minitablet
Description: Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
Study NCT01721798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena levonorgestrel IUD
Description: Intrauterine contraception system
Study NCT01721798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T-380a IUD
Description: intrauterine contraception system
Study NCT02617537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(YAZ,BAY86-5300)
Description: 0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
Study NCT02617537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for 28 days per 28-day intake cycle
Study NCT01962675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation + step training
Description: Direct current stimulation of motor cortex with low stimulation intensity
Study NCT01962675 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation + step training
Description: Stepping over specified soft foam obstacles
Study NCT01962675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation + step training
Description: Stepping over specified soft foam obstacles
Study NCT03521310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin-to-skin
Description: Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
Study NCT03521310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Neonates will get Conventional care the first 72 hours after birth
Study NCT00336544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethromycin
Description: Cethromycin 300 mg once per day (QD) for 7 days, administered orally
Study NCT00336544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Study NCT03699592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Home and Read Toolkit
Description: The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
Study NCT02870868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: Slow breathing techniques from yoga